Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: Involvement in tumor growth

PPAR Research

Volumn , Issue , 2008, Pages

  Grau, Raquel ^a   Díaz Muñoz, Manuel D ^a   Cacheiro Llaguno, Cristina ^a   Fresno, Manuel ^a   Iñiguez, Miguel A ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFIBRIC ACID; CYCLOOXYGENASE 2; FENOFIBRATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIRINIXIC ACID; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; DRUG TARGETING; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; MEDULLOBLASTOMA; METASTASIS; NONHUMAN; OVARY CANCER; PAIN; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; TESTIS CANCER; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 49749090062     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/352437     Document Type: Review

References (115)

1. Berger J., Moller D. E., The mechanisms of action of PPARs Annual Review of Medicine 2002 53 409 435
2. Corton J. C., Anderson S. P., Stauber A., Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators Annual Review of Pharmacology and Toxicology 2000 40 491 518
3. Michalik L., Wahli W., Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions Current Opinion in Biotechnology 1999 10 6 564 570
4. Schoonjans K., Staels B., Auwerx J., The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation Biochimica et Biophysica Acta 1996 1302 2 93 109
5. Wahli W., Braissant O., Desvergne B., Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more Chemistry and Biology 1995 2 5 261 266
6. Daynes R. A., Jones D. C., Emerging roles of PPARs in inflammation and immunity Nature Reviews Immunology 2002 2 10 748 759
7. Gelman L., Fruchart J.-C., Auwerx J., An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer Cellular and Molecular Life Sciences 1999 55 6-7 932 943
8. Michalik L., Desvergne B., Wahli W., Peroxisome-proliferator-activated receptors and cancers: complex stories Nature Reviews Cancer 2004 4 1 61 70
9. Fruchart J.-C., Duriez P., Staels B., Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis Current Opinion in Lipidology 1999 10 3 245 257
10. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 6294 645 650
11. Auboeuf D., Rieusset J., Fajas L., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor- α in humans: no alteration in adipose tissue of obese and NIDDM patients Diabetes 1997 46 8 1319 1327
12. Inoue I., Shino K., Noji S., Awata T., Katayama S., Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells Biochemical and Biophysical Research Communications 1998 246 2 370 374
13. Leone T. C., Weinheimer C. J., Kelly D. P., A critical role for the peroxisome proliferator-activated receptor α (PPAR α) in the cellular fasting response: the PPAR α -null mouse as a model of fatty acid oxidation disorders Proceedings of the National Academy of Sciences of the United States of America 1999 96 13 7473 7478
14. Willson T. M., Brown P. J., Sternbach D. D., Henke B. R., The PPARs: from orphan receptors to drug discovery Journal of Medicinal Chemistry 2000 43 4 527 550
15. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A., Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs The Journal of Biological Chemistry 1997 272 6 3406 3410
16. Xu H. E., Lambert M. H., Montana V. G., Molecular recognition of fatty acids by peroxisome proliferator-activated receptors Molecular Cell 1999 3 3 397 403
17. Forman B. M., Chen J., Evans R. M., Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4312 4317
18. Kliewer S. A., Sundseth S. S., Jones S. A., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4318 4323
19. Yu K., Bayona W., Kallen C. B., Differential activation of peroxisome proliferator-activated receptors by eicosanoids The Journal of Biological Chemistry 1995 270 41 23975 23983
20. Moraes L. A., Piqueras L., Bishop-Bailey D., Peroxisome proliferator-activated receptors and inflammation Pharmacology and Therapeutics 2006 110 3 371 385
21. Devchand P. R., Keller H., Peters J. M., Vazquez M., Gonzalez F. J., Wahli W., The PPAR α -leukotriene B4 pathway to inflammation control Nature 1996 384 6604 39 43
22. Calder P. C., n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases American Journal of Clinical Nutrition 2006 83 6 1505S 1519S
23. Calder P. C., Polyunsaturated fatty acids and inflammation Prostaglandins Leukotrienes and Essential Fatty Acids 2006 75 3 197 202
24. Madej A., Okopien B., Kowalski J., Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb International Journal of Clinical Pharmacology and Therapeutics 1998 36 6 345 349
25. Staels B., Koenig W., Habib A., Activation of human aortic smooth-muscle cells is inhibited by PPAR α but not by PPAR γ activators Nature 1998 393 6687 790 793
26. Marx N., Sukhova G. K., Collins T., Libby P., Plutzky J., PPAR α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 1999 99 24 3125 3131
27. Meissner M., Stein M., Urbich C., PPAR α activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation Circulation Research 2004 94 3 324 332
28. Marx N., Kehrle B., Kohlhammer K., PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis Circulation Research 2002 90 6 703 710
29. Delerive P., De Bosscher K., Besnard S., Peroxisome proliferator- activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF- κ B and AP-1 The Journal of Biological Chemistry 1999 274 45 32048 32054
30. Grau R., Punzón C., Fresno M., Iñiguez M. A., Peroxisome-proliferator-activated receptor α agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1 Biochemical Journal 2006 395 1 81 88
31. Mouthiers A., Baillet A., Deloménie C., Porquet D., Mejdoubi-Charef N., Peroxime proliferator-activated receptor α physically interacts with CCAAT/enhancer binding protein (C/EBP β) to inhibit C/EBP β -responsive α 1-acid glycoprotein gene expression Molecular Endocrinology 2005 19 5 1135 1146
32. Gervois P., Vu-Dac N., Kleemann R., Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β The Journal of Biological Chemistry 2001 276 36 33471 33477
33. Shipley J. M., Waxman D. J., Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) α and PPAR γ Molecular Pharmacology 2003 64 2 355 364
34. Delerive P., Martin-Nizard F., Chinetti G., Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway Circulation Research 1999 85 5 394 402
35. Desreumaux P., Dubuquoy L., Nutten S., Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPAR γ) heterodimer: a basis for new therapeutic strategies Journal of Experimental Medicine 2001 193 7 827 838
36. Irukayama-Tomobe Y., Miyauchi T., Sakai S., Endothelin-1-induced cardiac hyperthrophy is inhibited by activation of peroxisome proliferator-activated receptor- α partly via blockade of c-Jun NH2 -terminal kinase pathway Circulation 2004 109 7 904 910
37. Peters J. M., Cheung C., Gonzalez F. J., Peroxisome proliferator- activated receptor- α and liver cancer: where do we stand? Journal of Molecular Medicine 2005 83 10 774 785
38. Reddy J. K., Azarnoff D. L., Hignite C. E., Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens Nature 1980 283 5745 397 398
39. Lee S. S., Pineau T., Drago J., Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators Molecular and Cellular Biology 1995 15 6 3012 3022
40. Frick M. H., Elo O., Haapa K., Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease The New England Journal of Medicine 1987 317 20 1237 1245
41. Gariot P., Barrat E., Mejean L., Pointel J. P., Drouin P., Debry G., Fenofibrate and human liver. Lack of proliferation of peroxisomes Archives of Toxicology 1983 53 2 151 163
42. Ashby J., Brady A., Elcombe C. R., Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis Human and Experimental Toxicology 1994 13 supplement 2 S1 S117
43. Chevalier S., Roberts R. A., Perturbation of rodent hepatocyte growth control by nongenotoxic hepatocarcinogens: mechanisms and lack of relevance for human health Oncology Reports 1998 5 6 1319 1327
44. Gonzalez F. J., Shah Y. M., PPAR α: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators Toxicology 2008 246 1 2 8
45. Lawrence J. W., Li Y., Chen S., Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) α. PPAR α fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression The Journal of Biological Chemistry 2001 276 34 31521 31527
46. Palmer C. N. A., Hsu M.-H., Griffin K. J., Raucy J. L., Johnson E. F., Peroxisome proliferator activated receptor- α expression in human liver Molecular Pharmacology 1998 53 1 14 22
47. Collett G. P., Betts A. M., Johnson M. I., Peroxisome proliferator-activated receptor α is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma Clinical Cancer Research 2000 6 8 3241 3248
48. Suchanek K. M., May F. J., Robinson J. A., Peroxisome proliferator-activated receptor α in the human breast cancer cell lines MCF-7 and MDA-MB-231 Molecular Carcinogenesis 2002 34 4 165 171
49. Panigrahy D., Kaipainen A., Huang S., PPAR α agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition Proceedings of the National Academy of Sciences of the United States of America 2008 105 3 985 990
50. Jackson L., Wahli W., Michalik L., Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer Gut 2003 52 9 1317 1322
51. Segawa Y., Yoshimura R., Hase T., Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer The Prostate 2002 51 2 108 116
52. Hase T., Yoshimura R., Mitsuhashi M., Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists Urology 2002 60 3 542 547
53. Yoshimura R., Matsuyama M., Segawa Y., Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists International Journal of Cancer 2003 104 5 597 602
54. Urbanska K., Pannizzo P., Grabacka M., Activation of PPAR α inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines International Journal of Cancer 2008 123 5 1015 1024
55. Muzio G., Maggiora M., Trombetta A., Mechanisms involved in growth inhibition induced by clofibrate in hepatoma cells Toxicology 2003 187 2-3 149 159
56. Grabacka M., Plonka P. M., Urbanska K., Reiss K., Peroxisome proliferator-activated receptor α activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt Clinical Cancer Research 2006 12 10 3028 3036
57. Saidi S. A., Holland C. M., Charnock-Jones D. S., Smith S. K., In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer Molecular Cancer 2006 5, article 13 1 14
58. Shigeto T., Yokoyama Y., Xin B., Mizunuma H., Peroxisome proliferator-activated receptor α and γ ligands inhibit the growth of human ovarian cancer Oncology Reports 2007 18 4 833 840
59. Yokoyama Y., Xin B., Shigeto T., Clofibric acid, a peroxisome proliferator-activated receptor α ligand, inhibits growth of human ovarian cancer Molecular Cancer Therapeutics 2007 6 4 1379 1386
60. Tanaka T., Kohno H., Yoshitani S., Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats Cancer Research 2001 61 6 2424 2428
61. Maggiora M., Bologna M., Cerù M. P., An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines International Journal of Cancer 2004 112 6 909 919
62. Thuillier P., Anchiraico G. J., Nickel K. P., Activators of peroxisome proliferator-activated receptor- α partially inhibit mouse skin tumor promotion Molecular Carcinogenesis 2000 29 3 134 142
63. Grabacka M., Placha W., Plonka P. M., Inhibition of melanoma metastases by fenofibrate Archives of Dermatological Research 2004 296 2 54 58
64. Goetze S., Eilers F., Bungenstock A., PPAR activators inhibit endothelial cell migration by targeting Akt Biochemical and Biophysical Research Communications 2002 293 5 1431 1437
65. Varet J., Vincent L., Mirshahi P., Fenofibrate inhibits angiogenesis in vitro and in vivo Cellular and Molecular Life Sciences 2003 60 4 810 819
66. Pozzi A., Ibanez M. R., Gatica A. E., Peroxisomal proliferator-activated receptor- α -dependent inhibition of endothelial cell proliferation and tumorigenesis The Journal of Biological Chemistry 2007 282 24 17685 17695
67. Kaipainen A., Kieran M. W., Huang S., PPAR α deficiency in inflammatory cells suppresses tumor growth PLoS ONE 2007 2 2 e260
68. de Visser K. E., Eichten A., Coussens L. M., Paradoxical roles of the immune system during cancer development Nature Reviews Cancer 2006 6 1 24 37
69. Prestwich R. J., Errington F., Hatfield P., The immune system - is it relevant to cancer development, progression and treatment? Clinical Oncology 2008 20 2 101 112
70. Coussens L. M., Werb Z., Inflammation and cancer Nature 2002 420 6917 860 867
71. Mantovani A., Romero P., Palucka A. K., Marincola F. M., Tumour immunity: effector response to tumour and role of the microenvironment The Lancet 2008 371 9614 771 783
72. Aggarwal B. B., Shishodia S., Sandur S. K., Pandey M. K., Sethi G., Inflammation and cancer: how hot is the link? Biochemical Pharmacology 2006 72 11 1605 1621
73. Shiff S. J., Shivaprasad P., Santini D. L., Cyclooxygenase inhibitors: drugs for cancer prevention Current Opinion in Pharmacology 2003 3 4 352 361
74. Thun M. J., Henley S. J., Patrono C., Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues Journal of the National Cancer Institute 2002 94 4 252 266
75. Chen Y. Q., Edwards I. J., Kridel S. J., Thornburg T., Berquin I. M., Dietary fat-gene interactions in cancer Cancer and Metastasis Reviews 2007 26 3-4 535 551
76. Escrich E., Moral R., Grau L., Costa I., Solanas M., Molecular mechanisms of the effects of olive oil and other dietary lipids on cancer Molecular Nutrition and Food Research 2007 51 10 1279 1292
77. Morita I., Distinct functions of COX-1 and COX-2 Prostaglandins & Other Lipid Mediators 2002 68-69 165 175
78. Smith W. L., DeWitt D. L., Garavito R. M., Cyclooxygenases: structural, cellular, and molecular biology Annual Review of Biochemistry 2000 69 145 182
79. Tanabe T., Tohnai N., Cyclooxygenase isozymes and their gene structures and expression Prostaglandins & Other Lipid Mediators 2002 68-69 95 114
80. Simmons D. L., Botting R. M., Hla T., Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacological Reviews 2004 56 3 387 437
81. Dannhardt G., Kiefer W., Cyclooxygenase inhibitors - current status and future prospects European Journal of Medicinal Chemistry 2001 36 2 109 126
82. Marnett L. J., Recent developments in cyclooxygenase inhibition Prostaglandins & Other Lipid Mediators 2002 68-69 153 164
83. Subbaramaiah K., Dannenberg A. J., Cyclooxygenase 2: a molecular target for cancer prevention and treatment Trends in Pharmacological Sciences 2003 24 2 96 102
84. Eberhart C. E., Coffey R. J., Radhika A., Giardiello F. M., Ferrenbach S., Dubois R. N., Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 1994 107 4 1183 1188
85. Marnett L. J., DuBois R. N., COX-2: a target for colon cancer prevention Annual Review of Pharmacology and Toxicology 2002 42 55 80
86. Huls G., Koornstra J. J., Kleibeuker J. H., Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas The Lancet 2003 362 9379 230 232
87. Gupta R. A., DuBois R. N., Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 Nature Reviews Cancer 2001 1 1 11 21
88. Kawamori T., Rao C. V., Seibert K., Reddy B. S., Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis Cancer Research 1998 58 3 409 412
89. Gately S., The contributions of cyclooxygenase-2 to tumor angiogenesis Cancer and Metastasis Reviews 2000 19 1-2 19 27
90. Iñiguez M. A., Rodríguez A., Volpert O. V., Fresno M., Redondo J. M., Cyclooxygenase-2: a therapeutic target in angiogenesis Trends in Molecular Medicine 2003 9 2 73 78
91. Tegeder I., Pfeilschifter J., Geisslinger G., Cyclooxygenase-independent actions of cyclooxygenase inhibitors The FASEB Journal 2001 15 12 2057 2072
92. Jaradat M. S., Wongsud B., Phornchirasilp S., Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H2 synthases by ibuprofen, naproxen, and indomethacin Biochemical Pharmacology 2001 62 12 1587 1595
93. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A., Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs The Journal of Biological Chemistry 1997 272 6 3406 3410
94. Combs C. K., Bates P., Karlo J. C., Landreth G. E., Regulation of β -amyloid stimulated proinflammatory responses by peroxisome proliferator- activated receptor α Neurochemistry International 2001 39 5-6 449 457
95. Yu J., Ip E., Dela Peña A., COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator Hepatology 2006 43 4 826 836
96. Blann A. D., Belgore F. M., Constans J., Conri C., Lip G. Y. H., Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate American Journal of Cardiology 2001 87 10 1160 1163
97. Hanahan D., Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996 86 3 353 364
98. Folkman J., Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Medicine 1995 1 1 27 31
99. Carmeliet P., Jain R. K., Angiogenesis in cancer and other diseases Nature 2000 407 6801 249 257
100. Bergers G., Benjamin L. E., Tumorigenesis and the angiogenic switch Nature Reviews Cancer 2003 3 6 401 410
101. Liao D., Johnson R. S., Hypoxia: a key regulator of angiogenesis in cancer Cancer and Metastasis Reviews 2007 26 2 281 290
102. Hickey M. M., Simon M. C., Regulation of angiogenesis by hypoxia and hypoxia-inducible factors Current Topics in Developmental Biology 2006 76 217 257
103. Weidemann A., Johnson R. S., Biology of HIF-1 α Cell Death and Differentiation 2008 15 4 621 627
104. Kaidi A., Qualtrough D., Williams A. C., Paraskeva C., Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia Cancer Research 2006 66 13 6683 6691
105. Simiantonaki N., Jayasinghe C., Michel-Schmidt R., Peters K., Hermanns M. I., Kirkpatrick C. J., Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines International Journal of Oncology 2008 32 3 585 592
106. Pichiule P., Chavez J. C., LaManna J. C., Hypoxic regulation of angiopoietin-2 expression in endothelial cells The Journal of Biological Chemistry 2004 279 13 12171 12180
107. Rankin E. B., Giaccia A. J., The role of hypoxia-inducible factors in tumorigenesis Cell Death and Differentiation 2008 15 4 678 685
108. Ferrara N., VEGF: an update on biological and therapeutic aspects Current Opinion in Biotechnology 2000 11 6 617 624
109. Cross M. J., Claesson-Welsh L., FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition Trends in Pharmacological Sciences 2001 22 4 201 207
110. Ho Q. T., Kuo C. J., Vascular endothelial growth factor: biology and therapeutic applications International Journal of Biochemistry and Cell Biology 2007 39 7-8 1349 1357
111. Ferrara N., Gerber H.-P., LeCouter J., The biology of VEGF and its receptors Nature Medicine 2003 9 6 669 676
112. Shibuya M., Claesson-Welsh L., Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis Experimental Cell Research 2006 312 5 549 560
113. Shibuya M., Ito N., Claesson-Welsh L., Structure and function of vascular endothelial growth factor receptor-1 and -2 Current Topics in Microbiology and Immunology 1999 237 59 83
114. Griffioen A. W., Molema G., Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation Pharmacological Reviews 2000 52 2 237 268
115. Kasai T., Miyauchi K., Yokoyama T., Aihara K., Daida H., Efficacy of peroxisome proliferative activated receptor (PPAR)- α ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models Atherosclerosis 2006 188 2 274 280